Acute myeloid leukemia (AML) is a heterogeneous hematopoietic neoplasm which results in
clonal proliferation of abnormally differentiated hematopoietic cells. In this review …

Metabolic rewiring and cellular reprogramming are trademarks of neoplastic initiation and
progression in acute myeloid leukemia (AML). Metabolic alteration in leukemic cells is often …

Abstract Machine learning may aid the choice of optimal combinations of anticancer drugs
by explaining the molecular basis of their synergy. By combining accurate models with …

Abstract BCL-X L and BCL-2 are key anti-apoptotic proteins and validated cancer targets.
753B is a novel BCL-X L/BCL-2 proteolysis targeting chimera (PROTAC) that targets both …

Venetoclax is a highly selective B-cell lymphoma-2 (BCL-2) inhibitor, which, combined with
a DNA hypomethylating agent or low dose cytarabine, results in high rates of initial …

Extracellular vesicles hold great promise as a drug delivery platform for RNA-based
therapeutics. However, there is a lack of experimental evidence for the intracellular …

Simple Summary Treatment of acute myeloid leukemia continues to progress. Although a
number of therapies are efficacious in treating acute myeloid leukemia, some are intolerable …

Acute myeloid leukemia (AML) is a heterogeneous, aggressive malignancy with dismal
prognosis and with limited availability of targeted therapies. Epigenetic deregulation …

In recent years, one of the most promising advances in the treatment of acute myeloid
leukemia (AML) is the combination of a hypomethylating agent (HMA) with the BCL2 …

Venetoclax, a small-molecule B-cell lymphoma 2 (BCL-2) inhibitor, selectively eradicates
leukemic stem cells (LSCs). While venetoclax has revolutionized the treatment of acute …